soria

Great graphics and global overview on cancer prevalence and therapeutic improvements in this article. Overall cancer survival rates have moved from 50% end of the 70s to 67% in 2013.
ourworldindata.org/cancer

🧬 Early-onset colorectal cancer: a distinct tumor ecosystem?
• 🌐 Stromal enrichment: Younger MSS tumors exhibit ↑ stromal/epithelial ratio, validated in 712 tumors.
• 🔀 EMT signaling: ↑ inferred FN1, GDF, ACTIVIN & SPP1 interactions suggest enhanced tumor–stroma crosstalk.
• 🧬 Transcriptional rewiring: ↑ lncRNA expression, including poorly characterized transcripts, in younger MSS tumors.
• 🔬 Genomic landscape: CNA patterns largely conserved across ages, with a trend toward greater intratumoral heterogeneity (P=0.056).
• 🎯 Therapeutic opportunities: Stromal remodeling & EMT-associated signaling emerge as potential vulnerabilities.
📄 doi.org/10.1038/s41591…

🧬 Cancer Progress 2026: remarkable gains & a rapidly evolving therapeutic frontier fueled by science
• 📉 Mortality: US cancer death rate ↓ 35% since 1991 → >4.8M deaths averted
• 💊 Innovation: 11 new anticancer therapies FDA-approved in the past 12 months—10 molecularly targeted, including the first PROTAC in breast cancer
• 🛡️ Immunotherapy: 15 ICBs now span 23 cancer types
• 📈 Survival: 5-year survival across cancers reached 71% versus 49% in the mid-1970s
cancerprogressreport.aacr.org/progress/
#AACR

AI in Pharma R&D: time to move from better models → better medicines
• 🎯 Optimize what matters: improving Phase II success has far greater potential impact than simply accelerating hit discovery
• 💊 Ligand ≠ drug: AI can generate binders rapidly—but efficacy requires the right biology, exposure, safety & patient
• 🧬 Better data ≠ more data: biological data are highly contextual; what matters is predictive validity for human outcomes
• 📊 Benchmark ≠ impact: model accuracy matters only if it improves a real R&D decision—advance, redesign or stop
• 🔄 Next frontier: start with the clinical question → generate fit-for-purpose human biology → integrate clinical feedback → continuously improve the model
👉 Perhaps the end of the beginning: less “technology push,” more “science pull.”
#AI #DrugDiscovery #DrugDevelopment #PrecisionMedicine
nature.com/articles/s4157…

🦠 Programmable bacteria as cancer immunotherapy? A fascinating new study in STM
👏 Congratulations to Mathieu Rouanne, Nicholas Arpaia, & colleagues.
🔬 Engineered E. coli Nissle delivering CXCL13 directly into the bladder:
• Recruited & organized B- and T-cell immunity
• Induced tumor-specific antibodies
• Synergized with PD-1 blockade
• Produced durable tumor control and long-term survival in preclinical bladder cancer models
A compelling example of how synthetic biology could reshape the tumor immune microenvironment and expand the cancer immunotherapy toolbox.
📄 science.org/doi/10.1126/sc…